Literature DB >> 16304195

In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin.

George Pankey1, Deborah Ashcraft, Nalini Patel.   

Abstract

In vitro synergy testing of daptomycin plus rifampin was performed against 24 unique isolates of Enterococcus faecium resistant to both linezolid and vancomycin. Synergy testing showed that 21/24 (88%) were synergistic and 3/24 (12%) were indifferent by the Etest method. Time-kill assays revealed synergy for 18/24 (75%) and indifference for 6/24 (25%).

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16304195      PMCID： PMC1315941          DOI： 10.1128/AAC.49.12.5166-5168.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations.

Authors:  R L Akins; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

2.  Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001.

Authors:  Ian A Critchley; Renée S Blosser-Middleton; Mark E Jones; Clyde Thornsberry; Daniel F Sahm; James A Karlowsky
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

3.  Daptomycin dose-effect relationship against resistant gram-positive organisms.

Authors:  Raymond Cha; Richard G Grucz; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

4.  In vitro synergy of ciprofloxacin and gatifloxacin against ciprofloxacin-resistant Pseudomonas aeruginosa.

Authors:  George A Pankey; Deborah S Ashcraft
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

5.  Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid.

Authors:  A P Johnson; S Mushtaq; M Warner; D M Livermore
Journal:  Int J Antimicrob Agents       Date:  2004-10       Impact factor: 5.283

6.  Therapy of experimental staphylococcal mastitis in the mouse with cloxacillin and rifampicin, alone and in combination.

Authors:  N Craven; J C Anderson
Journal:  Res Vet Sci       Date:  1981-11       Impact factor: 2.534

7.  In vitro activity of daptomycin against vancomycin-resistant enterococci of various Van types and comparison of susceptibility testing methods.

Authors:  James H Jorgensen; Sharon A Crawford; Cynthia C Kelly; Jan E Patterson
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

8.  In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms.

Authors:  Maria Agnes Dawis; Henry D Isenberg; Kenneth A France; Stephen G Jenkins
Journal:  J Antimicrob Chemother       Date:  2003-04-14       Impact factor: 5.790

9.  Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci.

Authors:  Kenneth H Rand; Herbert Houck
Journal:  J Antimicrob Chemother       Date:  2004-02-12       Impact factor: 5.790

10.  Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms.

Authors:  Jennifer M Streit; Ronald N Jones; Helio S Sader
Journal:  J Antimicrob Chemother       Date:  2004-02-25       Impact factor: 5.790
View more
  22 in total

Review 1.  Combination antibiotic therapy for the treatment of infective endocarditis due to enterococci.

Authors:  Sebastiano Leone; Silvana Noviello; Silvano Esposito
Journal:  Infection       Date:  2015-09-01       Impact factor: 3.553

2.  Zidovudine (AZT) has a bactericidal effect on enterobacteria and induces genetic modifications in resistant strains.

Authors:  A Doléans-Jordheim; E Bergeron; F Bereyziat; S Ben-Larbi; O Dumitrescu; M-A Mazoyer; F Morfin; C Dumontet; J Freney; L P Jordheim
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-15       Impact factor: 3.267

3.  Peer reviewed publications in 2005.

Authors: 
Journal:  Ochsner J       Date:  2006

4.  Synergistic antimicrobial activities of folic acid antagonists and nucleoside analogs.

Authors:  Johannes Zander; Silke Besier; Hanns Ackermann; Thomas A Wichelhaus
Journal:  Antimicrob Agents Chemother       Date:  2009-12-22       Impact factor: 5.191

Review 5.  Bacterial resistance: a sensitive issue complexity of the challenge and containment strategy in Europe.

Authors:  W T M Jansen; J T van der Bruggen; J Verhoef; A C Fluit
Journal:  Drug Resist Updat       Date:  2006-06-27       Impact factor: 18.500

Review 6.  When does 2 plus 2 equal 5? A review of antimicrobial synergy testing.

Authors:  Christopher D Doern
Journal:  J Clin Microbiol       Date:  2014-06-11       Impact factor: 5.948

7.  Synergistic antibiotic effect of looped antimicrobial peptide CLP-19 with bactericidal and bacteriostatic agents.

Authors:  Di Li; Ya Yang; Zhiqiang Tian; Jun Lv; Fengjun Sun; Qian Wang; Yao Liu; Peiyuan Xia
Journal:  Oncotarget       Date:  2017-05-23

8.  Impact of Daptomycin Dose Exposure Alone or in Combination with β-Lactams or Rifampin against Vancomycin-Resistant Enterococci in an In Vitro Biofilm Model.

Authors:  Seyedehameneh Jahanbakhsh; Nivedita B Singh; Juwon Yim; Razieh Kebriaei; Jordan R Smith; Katherine Lev; T T Tran; Warren E Rose; Cesar A Arias; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

9.  In Vitro Synergy of Telavancin and Rifampin Against Enterococcus faecium Resistant to Both Linezolid and Vancomycin.

Authors:  George A Pankey; Deborah S Ashcraft
Journal:  Ochsner J       Date:  2013

Review 10.  A potential role for daptomycin in enterococcal infections: what is the evidence?

Authors:  Rafael Cantón; Patricia Ruiz-Garbajosa; Ricardo L Chaves; Alan P Johnson
Journal:  J Antimicrob Chemother       Date:  2010-04-02       Impact factor: 5.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.